Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Cited by (1,010)

Items 1,001–1,010 of 1,010

1. Clinico-genomic Characterization of <i>ATM</i> and HRD in Pancreas Cancer: Application for Practice
   Park, Wungki, O'Connor, Catherine A., Bandlamudi, Chaitanya, Forman, Daniella, Chou, Joanne F., Umeda, Shigeaki, Reyngold, Marsha, Varghese, Anna M., Keane, Fergus, Balogun, Fiyinfolu et al. · 2022 · Clinical Cancer Research
2. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS^G12DInhibitor, in Colorectal Cancer Treatment
   KATAOKA, MASAHIRO, KITAZAWA, MASATO, NAKAMURA, SATOSHI, KOYAMA, MAKOTO, YAMAMOTO, YUTA, MIYAZAKI, SATORU, HONDO, NAO, TANAKA, HIROKAZU, SOEJIMA, YUJI · 2023 · Anticancer Research
3. SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity
   Zheng, Wenfang, Yang, Zhiyi, Song, Ping, Sun, Yingchao, Liu, Pan, Yue, Lei, Lv, Kaiqi, Wang, Xinjie, Shen, Yuqin, Si, Jianmin et al. · 2023 · Cancer Letters
4. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
   Mondaca, Sebastian, Margolis, Matthew, Sanchez-Vega, Francisco, Jonsson, Philip, Riches, Jamie C., Ku, Geoffrey Y., Hechtman, Jaclyn F., Tuvy, Yaelle, Berger, Michael F., Shah, Manish A. et al. · 2019 · Gastric Cancer
5. HER3 Alterations in Cancer and Potential Clinical Implications
   Kilroy, Mary Kate, Park, SoYoung, Feroz, Wasim, Patel, Hima, Mishra, Rosalin, Alanazi, Samar, Garrett, Joan T. · 2022 · Cancers
6. A microglia clonal inflammatory disorder in Alzheimer’s disease
   Vicario, Rocio, Fragkogianni, Stamatina, Weber, Leslie, Lazarov, Tomi, Hu, Yang, Hayashi, Samantha Y, Craddock, Barbara, Socci, Nicholas D, Alberdi, Araitz, Baako, Ann et al. · 2025 · eLife
7. Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development
   Gmeiner, William H · 2021 · OncoTargets and Therapy
8. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues
   Voutsadakis, Ioannis A., Digklia, Antonia · 2023 · Chinese Clinical Oncology
9. Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
   Maruyama, Kohei, Shimizu, Yuki, Nomura, Yumi, Oh-hara, Tomoko, Takahashi, Yuki, Nagayama, Satoshi, Fujita, Naoya, Katayama, Ryohei · 2025 · npj Precision Oncology
10. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma
    Ecker, Brett L, Court, Colin M, Janssen, Quisette P, Tao, Alice J, D’Angelica, Michael I, Drebin, Jeffrey A, Gonen, Mithat, O’Reilly, Eileen M, Jarnagin, William R, Wei, Alice C et al. · 2022 · Journal of the American College of Surgeons